Cerebrovascular Accidents in Ranibizumab

Ueta, Takashi; Yanagi, Yasuo; Tamaki, Yasuhiro; Yamaguchi, Takuhiro

doi:10.1016/j.ophtha.2008.09.046

Cited by 111 publications

(75 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, monthly treatment with anti-VEGF agents may be associated with an increased risk of cerebrovascular incidents [59,60]. In our study none of the patients presented such adverse effects, probably due to the small number of subjects participating.…”

Section: Further Notes Of Interestcontrasting

confidence: 48%

Comparison of Combined Bevacizumab plus Dexamethasone Vs. Ranibizumab Monotherapy as First-Line Therapy in Patients with Treatment Naive Neovascular Age-Related Macular Degeneration in Real-Life Clinical Practice: A Retrospective Case-Series Analysis

Vakalis¹,

Echiadis²,

Deligiannis³

et al. 2017

J Clin Exp Ophthalmol

View full text Add to dashboard Cite

Purpose: To identify the differences between combination bevacizumab plus dexamethasone and ranibizumab in treatment naïve neovascular age-related macular degeneration in terms of functional/morphological outcomes and number of injections when evaluated in real-life clinical practice. Methods:We compared two groups of patients either receiving intravitreal bevacizumab (1.25 mg) plus dexamethasone sodium phosphate (0.2 mg) or intravitreal ranibizumab (0.5 mg) over a 12 month period. The former, Group A, received treatment at baseline and followed a pro re nata (PRN) regimen. The latter, Group B, received treatment at baseline followed by two additional monthly injections as per the universally accepted protocol whilst continuing treatment on PRN regimen thereafter. Best-corrected visual acuity (BCVA), intraocular pressure (IOP), slit-lamp fundus examination and central macular thickness (CMT) via optical coherence tomography (OCT) were recorded at the initial visit (Baseline, BSL) and at each subsequent follow-up visit.Results: CMT at BSL was 362.8 ± 45.4 μm in Group A and 358.3 ± 47.2 μm in Group B. At the end of the data analysis, CMT was improved substantially in both groups (246.1 ± 42.4 μm in Group A, 254.9 ± 21.2 μm in Group B), while BCVA improved as well (From 0.87 ± 0.15 logMAR to 0.48 ± 0.15 in Group A, from 0.81 ± 0.20 logMAR to 0.52 ± 0.10 in Group B). Group A received 248 injections, whereas Group B received 313. Conclusion:Combination treatment with DSP and bevacizumab provided the same efficacy and allowed a statistically significant reduction in the frequency of injections compared with ranibizumab monotherapy.

show abstract

Section: Further Notes Of Interestcontrasting

confidence: 48%

Comparison of Combined Bevacizumab plus Dexamethasone Vs. Ranibizumab Monotherapy as First-Line Therapy in Patients with Treatment Naive Neovascular Age-Related Macular Degeneration in Real-Life Clinical Practice: A Retrospective Case-Series Analysis

Vakalis¹,

Echiadis²,

Deligiannis³

et al. 2017

J Clin Exp Ophthalmol

View full text Add to dashboard Cite

show abstract

“…83 Fortunately, no similar association was seen with myocardial infarction. 84 Data regarding adverse events due to bevacizumab must be evaluated carefully because, unlike ranibizumab, which has had numerous such trials, bevacizumab has not been subjected to randomized sham-treated control groups. During the first few years of intravitreal bevacizumab use, a voluntary reporting site documented only rare incidences of systemic adverse events.…”

Section: Systemic Concernsmentioning

confidence: 99%

The Expanding Role of Vascular Endothelial Growth Factor Inhibitors in Ophthalmology

Stewart

2012

Mayo Clinic Proceedings

161

105

View full text Add to dashboard Cite

Vascular endothelial growth factor (VEGF) plays an important role in both physiologic and pathologic angiogenesis and contributes to increased permeability across both the blood-retinal and blood-brain barriers. After 2 decades of extensive research into the VEGF families and receptors, specific molecules have been targeted for drug development, and several medications have received US Food and Drug Administration approval. Bevacizumab, a full-length antibody against VEGF approved for the intravenous treatment of advanced carcinomas, has been used extensively in ophthalmology for exudative age-related macular degeneration, diabetic retinopathy, retinal vein occlusions, retinopathy of prematurity, and other chorioretinal vascular disorders. Pegaptanib and ranibizumab have been developed specifically for intraocular use, whereas the soon-to-be-introduced aflibercept (VEGF Trap-Eye) is moving through clinical trials for both intraocular and systemic use. Although these drugs exhibit excellent safety profiles, ocular and systemic complications, particularly thromboembolic events, remain a concern in patients receiving therapy. Patients experiencing adverse events that may be related to VEGF suppression should be carefully evaluated by both the ophthalmologist and the medical physician to reassess the need for intraocular therapy and explore the feasibility of changing medications. For this review a search of PubMed from January 1, 1985 through April 15, 2011, was performed using the following terms (or combination of terms): vascular endothelial growth factors, VEGF, age-related macular degeneration, diabetic retinopathy, retina vein occlusions, retinopathy of prematurity, intravitreal injections, bevacizumab, ranibizumab, and VEGF Trap. Studies were limited to those published in English. Other articles were identified from bibliographies of retrieved articles and archives of the author.

show abstract

“…SAILOR (intaokulinio Lucentis AGDD gydymui saugumo vertinimas) studija buvo IIIb fazės tęsinys MA-RINA ir ANCHOR klinikinių tyrimų, norint įvertinti ilgalaikį ranibizumabo saugumą ir efektyvumą. Rezultatai atskleidė insulto dažnio skirtumą naudojant skirtingas ranibizumabo dozes -0,3 ir 0,5 mg. Tačiau bendras atvejų skaičius buvo nedidelis, ir statistiškai patikimo skirtumo tyrime nebuvo gauta [63,64].…”

Section: Kraujagyslių Endotelinio Augimo Faktorių Inhibitorių Terapijaunclassified

Age-related macular degeneration treatment: current view (literature review)

Kalesinskaitė

Uljanionok

Liutkevičienė

2014

Medicinos Teorija Ir Praktika

View full text Add to dashboard Cite

sAntrAuKAReikšminiai žodžiai: amžinė geltonosios dėmės degeneracija, gydymas. Amžinė geltonosios dėmės degeneracija (AGDD) -tai geltonosios dėmės pažeidimas, lydimas ženklaus ir negrįžtamo centrinio matymo praradimo. Tai dažniausia vyresnių nei 60 metų žmonių aklumo priežastis. Visada pažeidžiamos abi akys, tačiau pažeidimas gali būti nevienodo intensyvumo. Pradinė AGDD diagnozuojama, kai nustatomos drūzos geltonojoje dėmėje ir tinklainės pigmentinio epitelio (TPE) pakitimai; vėlyvoji AGDD forma apima sausą AGDD (geografinė atrofija TPE, kai nėra neovaskulinės AGDD) ir neovaskulinę AGDD (TPE atšoka, kraujosruvos ir/ar randai). Deja, iki šiol nėra visiškai aiški ligos etiologija ir patogenezė, o gydymo galimybės ribotos ir ne visada efektyvios. Šiame straipsnyje trumpai apžvelgiamos pradinės ir vėlyvosios AGDD gydymo galimybės. AbstrActKey words: macular degeneration, exudative, nonexudative, treatment. Age-related macular degeneration (AMD) -is a damage of the macula, accompanied by a significant and irreversible loss of central vision. It is a major cause of blindness and visual impairment in older adults (>60 years). Damage of the retina always includes both eyes, though the intensity can vary. Early AMD is defined as the presence of drusen and retinal pigmentary abnormalities (RPE); late AMD includes dry AMD (geographic atrophy of the RPE in the absence of neovascular AMD) or neovascular AMD (detachment of the retinal pigment epithelium, hemorrhages, and/or scars). Unfortunately, the etiology and pathogenesis of AMD aren't fully understood up to now, so treatment options are limited and not always effective. This article briefly reviews the options of initial and late forms of AMD treatment. ĮVADASAmžinė geltonosios dėmės degeneracija (AGDD) -tai amžiaus sąlygota centrinės tinklainės dalies -geltonosios dėmės -degeneracinė liga, dažnai lydima ryškaus ir negrįž-tamo centrinės regos sutrikimo [1]. AGDD yra pagrindinė vyresnių nei 60 metų žmonių aklumo priežastis išsivysčiu-siose šalyse [2]. Manoma, jog maždaug 30 proc. suaugusiųjų (>75 metų) turi tam tikrų AGDD požymių ir apie 10 proc. šių pacientų liga diagnozuojama pažengusios ar vėlyvos stadijos [3]. Dėl progresuojančio centrinės regos sutrikimo ši liga turi didelę įtaką kasdienei veiklai, paciento savarankiškumui ir gyvenimo kokybei [4]. Nustatyta, kad amžiaus ilgėjimas yra natūralus AGDD rizikos veiksnys, todėl prognozuojama, jog toks vyresnio amžiaus žmonių skaičiaus augimas sąlygos dažnesnį aklumą. Atsižvelgiant į tai, PSO teigia, kad 2020 m. pasaulyje bus net 54 milijonai aklųjų, vyresnių nei 60 metų [5]. Amžinė geltonosios dė- Monika Kalesinskaitė

show abstract

Cerebrovascular Accidents in Ranibizumab

Cited by 111 publications

References 4 publications

Comparison of Combined Bevacizumab plus Dexamethasone Vs. Ranibizumab Monotherapy as First-Line Therapy in Patients with Treatment Naive Neovascular Age-Related Macular Degeneration in Real-Life Clinical Practice: A Retrospective Case-Series Analysis

Comparison of Combined Bevacizumab plus Dexamethasone Vs. Ranibizumab Monotherapy as First-Line Therapy in Patients with Treatment Naive Neovascular Age-Related Macular Degeneration in Real-Life Clinical Practice: A Retrospective Case-Series Analysis

The Expanding Role of Vascular Endothelial Growth Factor Inhibitors in Ophthalmology

Age-related macular degeneration treatment: current view (literature review)

Contact Info

Product

Resources

About